<DOC>
	<DOC>NCT00557011</DOC>
	<brief_summary>The purpose of this study is to assess, in a controlled environment, the efficacy and safety of NRP104 and Adderall XR compared to placebo in treatment of children, aged 6-12, with ADHD.</brief_summary>
	<brief_title>NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHD</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<mesh_term>Adderall</mesh_term>
	<criteria>males and nonpregnant females, aged 612 years DSMIVTR criteria for diagnosis of ADHD, combined or hyperactiveimpulsive subtypes on stable regimen of stimulants for at least one month in the last six months and has shown adequate response to stimulants without unacceptable side effects comorbid psychiatric diagnosis such as psychosis, bipolar illness, severe OCD, severe depressive or anxiety disorder history of seizure during the last 2 years, a tic disorder or Tourette's clinically significant ECG or laboratory abnormalities at screening or baseline taking clonidine or anticonvulsant drugs taking medications that affect blood pressure or heart rate</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>